This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

We wouldn't blame AlloVir, Inc. (NASDAQ:ALVR) shareholders if they were a little worried about the fact that Agustin Melian, the Chief Medical Officer & Head of Global Medical Sciences recently netted about US$2.3m selling shares at an average price of US$41.19. That sale reduced their total holding by 10% which is hardly insignificant, but far from the worst we've seen.

Check out our latest analysis for AlloVir

The Last 12 Months Of Insider Transactions At AlloVir

Over the last year, we can see that the biggest insider purchase was by Independent Non-Executive Director Morana Jovan-Embiricos for US$49m worth of shares, at about US$17.00 per share. We do like to see buying, but this purchase was made at well below the current price of US$43.70. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

Over the last year, we can see that insiders have bought 2.91m shares worth US$50m. But insiders sold 103.76k shares worth US$4.3m. Overall, AlloVir insiders were net buyers during the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. AlloVir insiders own about US$820m worth of shares (which is 30% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

What Might The Insider Transactions At AlloVir Tell Us?

Insiders sold AlloVir shares recently, but they didn't buy any. In contrast, they appear keener if you look at the last twelve months. And insider ownership remains quite considerable. So the recent selling doesn't worry us. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 4 warning signs for AlloVir (of which 2 are potentially serious!) you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

When trading AlloVir or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.